Related Experiment Video

Updated: Sep 18, 2025

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.7K

Beyond Transposons: TIGD1 as a Pan-Cancer Biomarker and Immune Modulator

Merve Gulsen Bal Albayrak1, Tuğcan Korak1, Gurler Akpinar1

  • 1Department of Medical Biology, Faculty of Medicine, Kocaeli University, Kabaoglu District, Baki Komsuoglu Blvd. No:21, Umuttepe, 41001 Kocaeli, Turkey.

Genes
|June 26, 2025
PubMed

Insights

Trigger Transposable Element Derived 1 (TIGD1) is an oncogene upregulated in many cancers, particularly colon adenocarcinoma. High TIGD1 expression correlates with poor prognosis and therapy resistance, suggesting its potential as a biomarker and therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Trigger Transposable Element Derived 1 (TIGD1) is a newly identified oncogene with incompletely understood functions.
  • Evidence suggests TIGD1's involvement in diverse cellular processes relevant to cancer development.
  • A comprehensive pan-cancer analysis is needed to clarify TIGD1's role in oncology.

Purpose of the Study:

  • To conduct a pan-cancer analysis of TIGD1 expression, diagnostic value, and prognostic significance.
  • To investigate TIGD1's association with the tumor immune microenvironment and response to immunotherapy.
  • To explore TIGD1's role in drug resistance and its potential as a therapeutic target.

Main Methods:

  • Utilized transcriptomic and clinical data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) projects.
  • Performed expression profiling, survival analysis, immune correlation studies, and gene set enrichment analysis.
  • Conducted single-cell sequencing and drug sensitivity assessments to evaluate TIGD1's functional impact.

Main Results:

  • TIGD1 was significantly upregulated across multiple cancer types, notably in colon adenocarcinoma.
  • Elevated TIGD1 expression correlated with poorer prognosis and was linked to resistance against Zoledronate, Dasatinib, and BLU-667.
  • TIGD1 expression associated with tumor immune microenvironment features, including immune checkpoint genes, TMB, and MSI, and implicated in oncogenic pathways.

Conclusions:

  • TIGD1 shows promise as a diagnostic and prognostic biomarker for colon, gastric, liver, and lung cancers.
  • TIGD1's modulation of anti-tumor immunity and association with therapy resistance highlight its potential as a novel target.
  • Further research into TIGD1 could lead to advancements in precision oncology and immunotherapeutic strategies.
Keywords:
TIGD1cancer prognosisdrug resistanceimmune microenvironmentimmunotherapymicrosatellite instabilitypan-cancer analysistumor mutational burden

More Related Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.8K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.8K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K